GlycoMimetics (NASDAQ: GLYC)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | -0.280 | 0.0300 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of GlycoMimetics (NASDAQ: GLYC) through any online brokerage.
Other companies in GlycoMimetics’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Cabaletta Bio (NASDAQ:CABA), Brooklyn (NASDAQ:BTX), Monopar Therapeutics (NASDAQ:MNPR) and Larimar Therapeutics (NASDAQ:LRMR).
The latest price target for GlycoMimetics (NASDAQ: GLYC) was reported by Jefferies on Friday, November 12, 2021. The analyst firm set a price target for 4.00 expecting GLYC to rise to within 12 months (a possible 609.98% upside). 1 analyst firms have reported ratings in the last year.
The stock price for GlycoMimetics (NASDAQ: GLYC) is $0.5634 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for GlycoMimetics.
GlycoMimetics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for GlycoMimetics.
GlycoMimetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.